A Dark Vector Cognition product

Item 6. EXHIBITS

6K characters. Original on sec.gov ·

Item 6. EXHIBITS

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

Exhibit No.Exhibit Description
10.1Form of AbbVie Inc. Performance-Vested Restricted Stock Unit Agreement*
10.2Form of AbbVie Inc. Performance Share Award Agreement*
10.3Form of AbbVie Inc. Non-Employee Director RSU Agreement (US)*
10.4Form of AbbVie Inc. Non-Qualified Stock Option Agreement*
10.5Form of AbbVie Inc. Retention RSU Agreement - Ratable Vesting*
31.1Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
31.2Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
32.1Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed on May 3, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Earnings; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) the Notes to Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101).

  • Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
2024 Form 10-Q | abbvieimage2a21.gif41

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABBVIE INC.
By:/s/ Scott T. Reents
Scott T. Reents
Executive Vice President,
Chief Financial Officer (Principal Financial Officer)

Date: May 3, 2024

2024 Form 10-Q | abbvieimage2a21.gif42

Previous: Item 5. OTHER ITEMS